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Estrogen Receptor-b (ERb) has been implicated in many cancers. In prostate and breast cancer its function
is controversial, but genetic studies implicate a role in cancer progression. Much of the confusion around
ERb stems from antibodies that are inadequately validated, yet have become standard tools for deci-
phering its role. Using an ERb-inducible cell system we assessed commonly utilized ERb antibodies and
show that one of the most commonly used antibodies, NCL-ER-BETA, is non-speciﬁc for ERb. Other
antibodies have limited ERb speciﬁcity or are only speciﬁc in one experimental modality. ERb is
commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ERb
expression in either, using validated antibodies and independent mass spectrometry-based approaches.
Our ﬁndings question conclusions made about ERb using the NCL-ER-BETA antibody, or LNCaP and MCF-
7 cell lines. We describe robust reagents, which detect ERb across multiple experimental approaches and
in clinical samples.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Estrogen receptor beta (ERb) was ﬁrst discovered in the rat
prostate (Kuiper et al., 1996). Since then, there has been consider-
able interest in understanding its role in both breast and prostate
cancer. Despite a large body of literature, the function of ERb in
these two cancers remains unclear (Haldosen et al., 2014; Nelson
et al., 2014). Most authors agree that ERb has a predominantly
antiproliferative, pro-apoptotic and tumor-suppressive role (Attia
and Ederveen, 2012; Bottner et al., 2014; Chang and Prins, 1999;
Ellem and Risbridger, 2007; Horvath et al., 2001; Madak-ErdoganCarroll).
Ireland Ltd. This is an open accesset al., 2013; McPherson et al., 2010; Muthusamy et al., 2011;
Nakajima et al., 2011; Rizza et al., 2014; Ruddy et al., 2014; Zhu et al.,
2004), however ERb has also been implicated as an oncogene. This
is particularly in the context of Castrate Resistant Prostate Cancer
(CRPC) where it has been proposed as a driver of androgen receptor
(AR)-dependent gene transcription (Yang et al., 2012, 2015), along
with a potential role in mediating the transition from hormone-
sensitive to CRPC (Zellweger et al., 2013). In breast cancer, it has
been suggested that ERbmay have a ‘bi-faceted role’ and should not
simply be considered a tumor-suppressor (Jonsson et al., 2014). ERb
has been reported to ‘cross-talk’ with androgen receptor-positive
breast cancer (Rizza et al., 2014) and may be an important factor
in ERa-negative breast cancer (Gruvberger-Saal et al., 2007; Smart
et al., 2013).
Inconsistencies in the reported expression of ERb in breast andarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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have contributed to this uncertainty. In prostate, most data support
the conclusion that ERb is highly expressed in benign epithelial
cells, with expression declining in cancer development and
inversely correlating with increasing Gleason grade (Asgari and
Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014;
Horvath et al., 2001; Leav et al., 2001; Risbridger et al., 2007).
However, it has also been reported that ERb expression is high in
bone and lymph node metastases (Bouchal et al., 2011; Zhu et al.,
2004) and that high ERb expression correlates with poor clinical
prognosis (Horvath et al., 2001; Zellweger et al., 2013). In breast
cancer, high ERb expression has been described both as a poor (Guo
et al., 2014) and favorable (Esslimani-Sahla et al., 2004;
Gruvberger-Saal et al., 2007; Hieken et al., 2015; Leygue and Mur-
phy, 2013; Myers et al., 2004; Omoto et al., 2002; Roger et al., 2001)
prognostic marker, with others ﬁnding no association between
clinico-pathological parameters and ERb expression (Umekita et al.,
2006).
It is recognized that there is wide variability in the sensitivity
and speciﬁcity of ERb antibodies, which may contribute to the
uncertainties surrounding its molecular action and tissue expres-
sion (Choi et al., 2001; Hartman et al., 2012; Skliris et al., 2002;
Weitsman et al., 2006; Wu et al., 2012). Previous ERb antibody
validation studies have been published (Carder et al., 2005; Choi
et al., 2001; Skliris et al., 2002; Weitsman et al., 2006; Wu et al.,
2012), however some of them are limited by reliance on two key
assumptions. Firstly, that when assessing an antibody by Western
blotting in a cell line model, the factor of interest is expressed and
secondly, when assessing an antibody's speciﬁcity by IHC in tissue,
the tissue expression of the factor has been well characterized. In
the case of ERb, these assumptions are problematic, as its expres-
sion in commonly used cell line models and in tissues is not uni-
versally accepted (Al-Bader et al., 2011; Asgari and Morakabati,
2011; Attia and Ederveen, 2012; Bouchal et al., 2011; Dey et al.,
2014; Gruvberger-Saal et al., 2007; Guo et al., 2014; Hieken et al.,
2015; Holbeck et al., 2010; Horvath et al., 2001; Leav et al., 2001;
Nakajima et al., 2011; Omoto et al., 2002; Risbridger et al., 2007;
Shaaban et al., 2003; Skliris et al., 2002; Umekita et al., 2006;
Zellweger et al., 2013; Zhou et al., 2012; Zhu et al., 2004).
In light of this, we sought to test and validate six commonly
used, commercially available ERb antibodies and two non-
commercially available ERb antibodies (Choi et al., 2001; Wu
et al., 2012) in a systematic manner that addresses these assump-
tions. To achieve this, we employed a number of assays for antibody
validation, including a novel proteomic-based pull down method
called Rapid Immunopreciptation Mass spectrometry of Endoge-
nous protein (RIME) (Mohammed et al., 2013). We then applied
successfully validated antibodies to cell line models of breast and
prostate cancer commonly used for studies of ERb to assess them
for ERb expression. ERb expression in the cell lines was validated by
a non-antibody dependent, targeted proteomics method known as
Parallel Reaction Monitoring (PRM) (Gallien et al., 2012). Finally,
benign and malignant prostate and breast tissues were stained
with the validated ERb antibody to assess tissue expression of ERb
by IHC.
2. Materials and methods
2.1. Cell culture
The cancer cell line MDA-MB-231 with doxycycline-inducible
ERb expression (MDA-MB-231-ERb) (Reese et al., 2014) was
cultured in Dulbeccos Modiﬁed Eagle Medium with F12 supple-
ment (DMEM/F12) with 10% heat-inactivated tetracycline-free fetal
bovine serum (FBS) (Fisher-Scientiﬁc), 2 mM L-glutamine, 50 U/mlpenicillin, 50 mg/ml streptomycin, 5 mg/ml blasticidin S (Invivogen)
to select for the tetracycline repressor and 500 mg/ml zeocin
(Invitrogen) to select for the ERb expression vector. To induce ERb
expression in MDA-MB 231-ERb cells, 15 cm2 plates were seeded
with 5  106 cells and doxycycline added at either 0.1 mg/ml (for
Western blot, real-time polymerase chain reaction (qRT-PCR) and
PRM) or 0.5 mg/ml (for RIME) for 24 h. The MCF-7 breast cancer cell
line was cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM)
with 10% heat-inactivated FBS (Fisher-Scientiﬁc), 2 mM L-gluta-
mine, 50 U/ml penicillin and 50 mg/ml streptomycin. The LNCaP
prostate cancer cell line was cultured in RPMI 1640 with 10% heat-
inactivated FBS (Fisher-Scientiﬁc), 2 mM L-glutamine, 50 U/ml
penicillin and 50 mg/ml streptomycin. All cells were incubated at
37 C with 5% CO2 and cultured to 80e90% conﬂuence. LNCaP and
MCF-7 cell lines were obtained from ATCC (Middlesex, UK) and
validated by STR genotyping.
2.2. Preparation of mRNA and qRT-PCR
MDA-MB-231-ERbþ, MDA-MB-231-ERbe, MCF-7 and LNCaP
cells were harvested for collection of mRNA using the RNEasy Mini
Kit (Qiagen, California USA). On-column DNase digestion was per-
formed to remove contaminating genomic DNA. RNA was quanti-
ﬁed with the NanoDrop 8000 (Thermo Scientiﬁc, Delaware USA).
Samples containing 250 ng random primers, 1 mg RNA, 1 ml 10 mM
dNTP mix and water to a total volume of 13 ml were heated to 65 C
for 5 min, followed by 1 min incubation on ice. To each sample 4 ml
5X First-strand buffer, 1 ml 0.1 M DTT, 1 ml RNaseOUT and 1 ml Su-
perScript III reverse transcriptase (RT) (Thermoﬁsher Scientiﬁc,
Leicestershire, UK) were added and incubated at 25 C for 5 min
then 50 C for 60 min followed by heating at 70 C for 15 min qRT-
PCR primers for wild type ERb (Table 1) were designed based on
published sequence of ESR2 (available from USCS genome browser
at http://genome.ucsc.edu/) using the Primer3 software package
(Koressaar and Remm, 2007; Untergasser et al., 2012) available at
http://bioinfo.ut.ee/primer3-0.4.0/primer3/. UBC primers
(SY121212648) were obtained from Sigma-Aldrich (Dorset, UK).
Each qRT-PCR reaction contained 7.5 ml Power SYBR Green PCR
Master Mix (Applied Biosystems, California USA), 0.5 ml of 10 mM
primer mix, 2 ml of a 1:5 dilution of cDNA and nuclease-free water
to a ﬁnal volume of 15 ml. Reactions were performed with the
Stratagene Mx3005P RealTime machine in triplicate. Hot-start Taq
polymerase was heat-activated at 95 C for 10 min followed by 40
cycles of 15 s at 95 C and 30 s at 60 C. Fluorescence was read in
each cycle and a melting curve constructed as the temperature was
increased from 65 C to 95 C with continuous ﬂuorescence read-
ings. UBC was used as a control gene to normalize between the
samples and relative expression determined using the delta-delta
Ct method (Livak and Schmittgen, 2001).
2.3. Western blotting
MDA-MB-231-ERbþ, MDA-MB-231-ERbe, MCF-7 and LNCaP
cells were harvested for nuclear extract using the Ne-Per nuclear
extraction kit (Thermo Scientiﬁc Pierce, Rockford IL USA) according
to the manufacturer's instructions. Extracted protein was quanti-
ﬁed using the Direct Detect system (Merrick Millipore, Massachu-
setts USA). Nuclear extracts were prepared with 4X protein sample
loading buffer (LI-COR Biosciences, USA), 10X NuPage sample
reducing agent (Thermoﬁsher Scientiﬁc, Leicestershire, UK) and
water, and 15 mg protein per lane loaded into Bolt 4e12% Bis-Tris
gels (Thermoﬁsher Scientiﬁc, Leicestershire, UK). Gels were run
with MOPS running buffer for 30 min at 60 V followed by 30 min at
120 V. Western transfer was performed using the iBlot system
(Invitrogen, Paisley, UK) according to the manufacturer's
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was added to membranes for one hour at room temperature. Pri-
mary antibodies (Table 2 and Supplementary Fig. 1) were added at
the following dilutions and incubated overnight at 4 C:
Novocastra-ER-beta (EMR02-NCL-ER-BETA) (Leica Biosystems,
Newcastle, UK) 1:100, ERb1 PPG5/10 (MAI-81281) (Thermo Scien-
tiﬁc Pierce, Rockford IL USA) 1:100, ERb-antibody H150 (sc8974)
(Santa Cruz Biotechnology, Dallas TX, USA) 1:200, CWK-F12, USA)
(Choi et al., 2001) 1:200, MC10 (Wu et al., 2012) 1:300, GeneTex
ERb 70182 (Irvine, CA, USA) 1:200, ERb 06-629 (Merck Millipore,
Watford, UK), 1:500, Abcam 288 [14C8] (Cambridge, UK) 1:500. The
following were used as loading controls: rabbit anti-beta actin
(ab8227) (Abcam, Cambridge, UK) 1:5000 or mouse anti-beta actin
[AC-15](ab6276) 1:1000 according to the species of the ERb anti-
body. The membranes were washed three times with PBS/0.1%
tween and incubated with secondary antibodies for one hour at
room temperature: Goat anti-mouse (green) 1:5000 with Goat
anti-rabbit (red) 1:20000 or Goat anti-rabbit (green) 1:5000 with
Goat anti-mouse (red) 1:20000 according to the species of the ERb
antibody. Membranes were imaged using the Li-Cor Odyssey ﬂuo-
rescent imaging system (LI-COR Biosciences, USA).
2.4. Immunohistochemistry (IHC)
Formalin-ﬁxed, parafﬁn-embedded MDA-MB-231-ERbe and
MDA-MB-231-ERbþ cell pellets were generated, with ~2 107 cells
per pellet. ERb expression was induced with 0.5 mg/ml doxycycline
for 24 h. Antigen retrieval was achieved by incubating in citrate-
based retrieval solution for 20 min. Sections were stained using
CWK-F12 ERb antibody, diluted 1:250 in standard Bond diluent
using Leica's Polymer Reﬁne Kit (Catalogue No: DS9800) on the
automated Bond platform (Leica Biosystems Newcastle Ltd, New-
castle UK). Images were captured using Aperio® software (Leica
Biosystems Newcastle Lt, Newcastle UK).
A prostate tissue microarray (TMA) was created from a random
selection of prostate cancers, including a range of different tumor
grades, and benign prostatic tissue (10 cancer, 5 benign in total)
(ethical approval: ProMPT study MREC/01/4/061). The areas to be
sampled from the formalin-ﬁxed and parafﬁn embedded tissue
blocks were marked on the corresponding Haematoxylin and Eosin
stained parafﬁn sections. Each block was assessed to ensure that
there was an adequate amount of tissue for sampling, and cores of
tissue punched from the selected area of the block using 5 mm skin
biopsy punches. Each core was re-embedded into a new recipient
parafﬁn block and its position in the block recorded on a TMAmap.
Cores of pig kidney were used as orientation markers.
The breast TMA was constructed using the Chemicon Advanced
Tissue Arrayer (Merck Millipore, Germany) according to the man-
ufacturer's instructions. This contained 30 benign samples, 56
grade I, 55 grade II and 57 grade III ER alpha positive tumors. An
additional TMA was constructed from 10 invasive carcinomas and
10 non-malignant tissues for optimisation of antibody staining. To
ensure adequate representation of the tissue, core size of 1 mmwas
selected and cores arranged in duplicate with liver and spleen as
orientation cores. The study protocol for tissue collection was
approved by the University of Adelaide Human Research EthicsTable 1
Sequence of ERbmRNA primers used in qRT-PCR validation of theMDA-MB-
231-ERb cell line. These primer sequences ﬂank a region spanning exons 2
and 3, which is common to wild type ERb and ERb isoforms.
Primer Sequence
ERb e fwd 50 AAAACCGGCGCAAGAGCTG 30
ERb e rev 30 TGCTCGTCGGCACTTCTCTG 50Committee (#s H-2005-065).
For the prostate IHC, 3.5 mm sections were cut and mounted
onto charged slides, dried and sealed with parafﬁn. The CWK-F12
ERb antibody was further optimized to the clinical samples and
diluted at 1:200 in diluent consisting of 1% donkey serum, 0.05%
Tween20 in 300 mM TBS to reduce background staining. Antigen
retrieval was achieved by incubating in Tris EDTA for 20 min at
100 C. Images were captured at 250  magniﬁcation using Image
Pro-Insight (Media Cybernetics. Rockville, MD. USA).
For the breast IHC, 4 mm sections were cut and adhered to
Superfrost UltraPLUS slides (Thermo-Fisher Scientiﬁc
#1014356190). Slides were dewaxed in xylene followed by 100%
EtOH and then PBS. Endogenous peroxidase was quenched with
0.3% hydrogen peroxide (Ajax Finchem ##7722-84-1). Antigen
retrieval was performed in 10 mM Citric acid buffer (pH 6.0) within
a decloaking chamber (Biocare Medical #DC2012), for 5 min at
120 C. Slides were blocked in 5% normal goat serum (Sigma-
Aldrich #G9023) in PBS for 30 min at room temperature. CWK-F12
antibody was added at a dilution of 1:100 and incubated overnight
at 4 C. A second section of TMA tissue that received buffer in the
absence of primary antibody served as a negative control. Sec-
ondary antibody (biotinylated anti-mouse antibody (Dako #E0433)
diluted in PBS with 5% normal goat serumwas added and incubated
for 60min at room temperature. Sections werewashed twice in PBS
followed by addition of HRP-conjugated streptavidin (Dako
#P0397). Tissue was counterstained with haematoxylin and
mounted under DPX mountant (Sigma #06522). Slides were
scanned on a Nanozoomer slide scanner (Hamamatsu #C9600).
2.5. Rapid immunoprecipitation and Mass Spectrometry of
Endogenous Protein (RIME)
RIME experiments were conducted as previously described
(Mohammed et al., 2013). Brieﬂy, MDA-MB-231-ERbþ, MDA-MB-
231-ERbe (2  107 cells per condition for antibody evaluation),
LNCaP and MCF-7 cells (4  107 cells per condition for cell line
characterization) were grown in 15 cm2 plates to 90% conﬂuency.
Cells were crosslinked with media containing 1% EM grade form-
aldehyde (TEBU biosciences, Peterborough UK) for 8 min and the
formaldehyde quenched with 0.1 M glycine. Cells were washed,
harvested and pelleted in cold PBS. To enrich the nuclear fraction
the cell pellet was suspended in 10 ml of lysis buffer 1 (50 mM
HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5%
NP-40 or Igepal CA-630, and 0.25% Triton X-100) for 10 min at 4 C.
Cells were pelleted and resuspended in lysis buffer 2 (10 mM Tris-
HCL [pH 8.0], 200 mMNaCl, 1 mM EDTA, and 0.5 mM EGTA) for ﬁve
minutes at 4 C. Cells were pelleted and resuspended in 300 ml of
lysis buffer 3 (10 mM Tris-HCl [pH 8], 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine)
and sonicated (Diagenode bioruptor. Diagenode, Seraing Belgium)
for 45 min 30 ml of 10% Triton-X was added and the sonicated lysate
centrifuged at 17,000G for 10 min to remove cell debris. The su-
pernatant was incubated with 100 ml of magnetic beads (Dyna-
beads®, Thermo Fisher Scientiﬁc, Waltham MA USA) pre-bound
with antibody.
For evaluation of the 8 ERb antibodies, immunoprecipitations
(IP) were set up each for MDA-MB-231-ERbe and MDA-MB-231-
ERbþ cells using 10 mg of antibody (NCL-ER-BETA, GeneTex
70182, Millipore 06-629, Abcam 288 [14C8], MC10, CWK-F12,
sc8974 and PPG5/10). For characterization of LNCaP and MCF-
7 cells, 20 mg of MC10 ERb antibody was used in each IP. In all cases,
10 mg of E2F1-C20 IP was used as a positive control (Sc-193, Santa
Cruz Biotechnology, Dallas TX, USA) and species-speciﬁc IgG used
to detect non-speciﬁc pull-down (Mouse sc2025 or Rabbit sc2027,
Santa Cruz Biotechnology, Dallas TX, USA). Samples were incubated
Table 2
Details of ERb antibodies validated. Application details are as recommended by the manufacturer. IHC, immunohistochemistry; WB, western blot; IF, immunoﬂuorescence;
ChIP, chromatin immunoprecipitation; ELISA, enzyme-linked immunosorbent assay; Flow cyt, ﬂow cytometry; ICC, immunocytochemistry; IP, immunoprecipitation; Wt, wild
type; NTD, N terminal domain; LBD, ligand binding domain.
Antibody Immunogen Host species Class Binding region Application
NCL-ER-BETA Recombinant protein. Wt ERb. C terminus Mouse Monoclonal C terminus IHC, WB
PPG5/10 Synthetic peptide C terminus of wt ERb Mouse Monoclonal C terminus IF, IHC, WB
GeneTex 70182 Amino acids 1-153 of human ERb expressed in E.coli Mouse Monoclonal N terminus IP, WB, ChIP
Millipore 06-629 Amino acids 46-63 of human ERb Rabbit Polyclonal NTD WB, IHC
Santa cruz sc8974 Amino acids 1-150 of human ERb Rabbit Polyclonal N terminus WB, ChIP, IF, ELISA
Abcam 288 [14C8] Recombinant fusion protein. Amino acids 1-153 of human ERb in E.coli Mouse Monoclonal N terminus WB, Flow cyt, IHC, ICC, ChIP
CWK-F12 Recombinant protein. Amino acids 272-285 of human wt ERb Mouse Monoclonal LBD WB, IP, IHC
MC10 Fusion protein. Amino acids 1-140 of human ERb in E.coli Mouse Monoclonal N terminus IHC, IP, WB, IF
A.W. Nelson et al. / Molecular and Cellular Endocrinology 440 (2017) 138e150 141overnight at 4 C. Beads were washed 10 times in 1 ml RIPA buffer
(50mMHEPES pH 7.6,1mM EDTA, 0.7% Na deoxycholate,1% NP-40,
0.5 M LiCL) and twice in 100 mM ammonium hydrogen carbonate
(AMBIC) solution. Dry, frozen beads were submitted for tryptic
digestion of bead-bound protein, and peptides pulled down by IP
identiﬁed by mass-spectrometry (LTQ Velos-Orbitrap MS, Thermo
Fisher Scientiﬁc, Waltham MA USA). Raw MS data ﬁles were pro-
cessed using Proteome Discoverer v.1.3 (Thermo Scientiﬁc). Pro-
cessed ﬁles were searched against the SwissProt human database
using the Mascot search engine version 2.3.0 with a false discovery
rate (FDR) of less than 1%. For each ERb antibody tested, the
resulting list of puriﬁed peptides identiﬁed was ﬁltered against the
corresponding IgG control to remove non-speciﬁc proteins pulled
down. Mean percentage ERb peptide coverage, and mean number
of unique ERb peptides identiﬁed in biological duplicate experi-
ments were calculated.
2.6. Parallel Reaction monitoring (PRM)
Nuclear pellets of MDA-MB-231-ERbþ, MDA-MB-231-ERbe,
LNCaP and MCF-7 cells were prepared using the Panomics nuclear
extraction kit (Affymetrix, CA USA) as per the manufacturer's pro-
vided instructions. Nuclear pellets were lysed in 8 M Urea, 0.1% SDS
in 50 mM TEAB by sonication twice, each for 5 min. After protein
estimation 20 mg of protein was taken for tryptic digestion. 50 mM
of TEAB (pH¼ 8) was added up to a total volume of 100 ml. Cysteines
were reduced in 0.1 mM DTT for 1 h at room temperature and
alkylated in 0.1 mM IAA for 30 min at room temperature in the
dark. Alkylation was quenched by adding 0.1 mM DTT for 15 min.
Trypsin (Promega trypsin (V5111)) was added in a 1:100 trypsin:-
protein ratio for 1 h at room temperature. Another batch of trypsin
(1:100 ratio) was added to have a ﬁnal ratio of 1:50 for incubation
overnight. Samples were acidiﬁed to a ﬁnal concentration of 1%
formic acid (FA) and cleaned over C18 spin columns (Harvard
apparatus C18 Micro SpinColumn™). After elution from the col-
umns samples were lyophilized in a speedvac and resolubilized in
0.1% FA, 5% ACN to a ﬁnal peptide concentration of 1 mg/ml. Samples
were subjected to liquid chromatography-electrospray ionization
in an Orbitrap nano-ESI Q-Exactive mass spectrometer (Thermo
Scientiﬁc), coupled to a nanoLC (Dionex Ultimate 3000 UHPLC).
Samples were trapped on a 100 mm 2 cm, C18, 5 mm,100 trapping
column (Acclaim PepMap 100) in mL-pickup injection mode at 4 mL/
min ﬂow rate for 10 min. Samples were loaded on a Rapid Sepa-
ration Liquid Chromatography, 75 mm  25 cm nanoViper C18 3 mm
100 column (Acclaim, PepMap) retroﬁtted to an EASY-Spray source
with a ﬂow rate of 300 nL/min (buffer A, HPLC H2O, 0.1% FA; buffer
B, 100% ACN, 0.1% FA; 60-min gradient; 0e5 min: 5% buffer B,
5e45 min: 5 to >56% buffer B, 45.1e50 min: 56% to >95% buffer B,
50.1e60 min, 5% buffer B). Peptides were transferred to the gaseous
phase with positive ion electrospray ionization at 1.8 kV. Precursors
were targeted in a 2Th selectionwindow around them/z of interest.Precursors were fragmented in high-energy collisional dissociation
mode with normalized collision energy dependent on the target
peptide. The ﬁrst mass analysis was performed at a 70,000 reso-
lution, an automatic gain control target of 3  106, and a maximum
C-trap ﬁll time of 200 ms; MS/MS was performed at 35,000 reso-
lution, an AGC target of 5  104, and a maximum C-trap ﬁll time of
100 ms. Spectra were analyzed using Skyline with manual
validation.
2.7. Statistics
Differences in ERbmRNA levels observed inMDA-MB-231-ERbe
and MDA-MB-231-ERbþ conditions were analyzed using unpaired
t-tests. Differences were considered statistically signiﬁcant at
p  0.05. Data presented are mean of technical triplicate
experiments ± standard deviation. Analysis was performed in
GraphPad Prism version 6.
3. Results
3.1. ERb antibody validation
Given the confusion in the ERb ﬁeld and the concern associated
with variable and potentially non-speciﬁc reagents, we sought to
extensively validate commonly used ERb antibodies in a systematic
manner that does not rely upon a priori assumptions regarding ERb
expression in cell line models or in tissues. As a control, we
employed a cell line system with doxycycline-inducible expression
of the ERb protein, allowing us to assess antibodies in ERb negative
and matched ERb positive conditions (Fig. 1A). One hundred-fold
induction of ERb mRNA in MDA-MB-231-ERb cells treated with
doxycycline 0.1 mg/ml for 24 h (p¼ 0.01) was conﬁrmed by qRT-PCR
(Fig. 1B).
Western blots of MDA-MB-231-ERbþ and MDA-MB-231-ERbe
cell lysates with 8 different ERb antibodies were performed
(Fig. 1C). Six commonly used antibodies in the literature were
included; PPG5/10 (Asgari and Morakabati, 2011; Carder et al.,
2005; Ciucci et al., 2014; Shaaban et al., 2003; Wimberly et al.,
2014), NCL-ER-BETA (Ellem et al., 2014; Hussain et al., 2012;
McPherson et al., 2007; 2010; Morais-Santos et al., 2015; Oliveira
et al., 2007; Umekita et al., 2006; Yang et al., 2015; Zellweger
et al., 2013), Genetex 70182 (Celhay et al., 2010; Madak-Erdogan
et al., 2013; Mak et al., 2013, Mak et al., 2015, ; Nakajima et al.,
2011), Millipore 06-629 (Bouchal et al., 2011; Chen et al., 2009;
Grubisha et al., 2012), Abcam 288 [14C8] (Abd Elmageed et al.,
2013; Carder et al., 2005; Colciago et al., 2014; Cotrim et al., 2013;
Dey et al., 2012, 2014; Setlur et al., 2008; Shaaban et al., 2003;
Vivar et al., 2010; Yang et al., 2012) and Santa Cruz 8974 (Al-
Bader et al., 2011; Foryst-Ludwig et al., 2008; Han et al., 2015;
Rossi et al., 2011; Zhou et al., 2012) antibodies. The PPG5/10 anti-
body detected a protein band of 77 kDawith no difference between
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speciﬁc protein. Similarly, the NCL-ER-BETA antibody detected a
band of ~59 kDa, which is the correct size for ERb however, there
was no difference between ERbþ or ERbe conditions implying that
this band was not ERb. The GeneTex 70182 antibody detected a
band of 59 kDa with differential signal between ERbþ and ERbe
conditions, and a non-speciﬁc band was present at around 65 kDa.
The Millipore 06-629 antibody detected a band of 59 kDa in both
ERbþ and ERbe conditions, however the band was stronger in the
ERbþ condition, suggesting that the antibody could be cross-
reacting with another protein of 59 kDa in addition to detecting
ERb. MC10, CWK-F12, Abcam 288 [14C8] and sc8974 ERb antibodies
all detected protein bands of 59 kDa with differential signal be-
tween ERbþ and ERbe conditions, conﬁrming their speciﬁcity for
ERb by Western blotting. Further conﬁrmation of the speciﬁcity of
CWK-F12 to ERb was demonstrated by IHC of MDA-MB-231-ERbþ
and MDA-MB-231-ERbe cell pellets (Fig. 2), showing differential
nuclear staining between the two conditions. The 8 ERb antibodies
were then assessed by an independent method called RIME, which
uses an antibody-based puriﬁcation followed by mass spectrom-
etry (MS) to identify enriched peptides. We conducted RIME in
MDA-MB-231-ERbe and MDA-MB-231-ERbþ cells using all 8 an-
tibodies. E2F1 antibody was included in parallel as a positive con-
trol since E2F1 is a ubiquitous protein (Fig. 3A) and an IgG was used
as a negative control (Fig. 3C). In MDA-MB-231-ERbe cells, no ERb
peptides were puriﬁed by any of the ERb antibodies, conﬁrming the
ERb negative status of the uninduced MDA-MB-231-ERb cell line
(Fig. 3C). Following ERb induction, RIME revealed diverse coverage
of the ERb protein by the different antibodies. The percent coverage
of the ERb protein following puriﬁcation with each of the ERb an-
tibodies, and the location of the peptide fragments identiﬁed byMS
are shown in Fig. 3B. To provide an indication of the speciﬁcity of
each antibody, we ranked all the proteins puriﬁed by the IP and
identiﬁed by MS according to the number of unique peptides
(conﬁrmed with a false discovery rate (FDR) of <1%). We hypoth-
esized that the higher the ranking of ERb, the greater the speciﬁcity
of the antibody. Hence, if ERb has the greatest number of unique
peptides relative to all other proteins, it is ranked 1st.
NCL-ER-BETA did not purify any ERb peptides (Fig. 3B), which is
consistent with the lack of speciﬁcity identiﬁed from the Western
blot result (Fig.1C). TheMillipore 06-629 antibody positively pulled
down ERb in the test condition, although coverage and ranking
were not as favorable as compared with some of the other anti-
bodies. Interestingly, LACTB, a 60 kDa protein was puriﬁed by
Millipore 06-629 in both ERbþ and ERbe conditions (data not
shown), which may explain the ~60 kDa band identiﬁed from
Western blotting. Whilst the PPG5/10 did not detect ERb by
Western blotting, by RIME it detected ERb with 25% coverage, with
ERb ranking 3rd in the list of identiﬁed peptides, suggesting dif-
ferences in the speciﬁcity of this antibody from one experimental
assay to another. PPG5/10 has been previously validated for IHC in a
doxycycline-inducible U2OS-ERb cell line, developed using the
same plasmids as the MDA-MB-231-ERb cell line (Wu et al., 2012).
The Abcam 288 [14C8] antibody is a very commonly used ERb
antibody (Abd Elmageed et al., 2013; Colciago et al., 2014; Cotrim
et al., 2013; Dey et al., 2012, 2014; Setlur et al., 2008; Shaaban
et al., 2003; Vivar et al., 2010; Yang et al., 2012), which performed
well by Western blotting, and also had the best antibody coverage
by RIME (31.9%). However ERb ranked 20th in the list of identiﬁed
peptides when using Abcam 288 [14C8], suggesting that this anti-
body might also be purifying additional non-speciﬁc proteins. The
MC10 antibody had the second-greatest coverage (28.2%) with ERb
ranking 1st in the list of identiﬁed peptides. In view of this ﬁnding,
along with the positive Western blot result (Fig. 1), the MC10
antibody was carried forward into the RIME experiments for thecell line characterization. The CWK-F12 antibody had 17.7%
coverage, with ERb ranking 2nd in the list of puriﬁed peptides. As
the CWK-F12 antibody produced very clean results by Western
blotting, IHC and ranked ERb second in the list of puriﬁed proteins,
it was used forWestern blotting in the cell line characterization and
directly compared against the non-speciﬁc NCL-ER-BETA antibody.
The goal was to use independent validated ERb antibodies and
additional independent methods to assess whether the most
commonly studied breast and prostate cancer cell line models ex-
press ERb.
3.2. Characterization of LNCaP and MCF-7 cell lines for ERb
expression
Given the wealth of publications assessing ERb in breast (MCF-
7) and prostate (LNCaP) cancer cell lines (Abd Elmageed et al., 2013;
Al-Bader et al., 2011; Bouchal et al., 2011; Chen et al., 2009; Dey
et al., 2014; Ellem et al., 2014; Fuqua et al., 1999; Hinsche et al.,
2015; Kim et al., 2002; Lau et al., 2000; Mak et al., 2013; Shaaban
et al., 2003; Skliris et al., 2002; Weng et al., 2013; Yang et al., 2012,
2015; Zhou et al., 2012), we sought to investigate the expression of
ERb in these models, using the newly validated ERb antibodies.
Protein lysate and RNA was collected from LNCaP and MCF-7 cells.
Using primers validated in the inducible MDA-MB-231-ERb cell
line, which binds to sequence common towild type (wt) ERb and its
isoforms (Fig. 1B), LNCaP and MCF-7 were shown to express no
detectable levels of ERb mRNA (Fig. 4A). Using the validated CWK-
F12 ERb antibody, ERb protein was undetectable by Western blot-
ting in these cells. By way of contrast, using the NCL-ER-BETA
antibody on the same cell lysates, we detected a protein band of
approximately 59 kDa in all conditions tested, including the MDA-
MB-231-ERbe cell line, conﬁrming the non-speciﬁcity of this
antibody to ERb (Fig. 4B). Importantly, this demonstrates that the
NCL-ER-BETA antibody is not detecting ERb in either LNCaP orMCF-
7 cancer cell line models and is instead identifying a non-speciﬁc
protein of similar molecular weight.
Furthermore, RIME analysis of LNCaP and MCF-7 cells using the
validatedMC10 ERb antibody did not purify any ERb peptides byMS
(Fig. 4C). This result was conﬁrmed by an antibody-independent
approach known as Parallel Reaction Monitoring (PRM), which
demonstrated that no ERb peptides were present in either of these
cell lines (Fig. 4D). As such, our early passage LNCaP and MCF-7 cell
line models are ERb negative and these cancer models should not
be used for the analysis of this protein.
3.3. ERb expression in prostate and breast tissue
Importantly, whilst the LNCaP and MCF-7 cell-line models do
not express ERb, application of the validated CWK-F12 ERb anti-
body to prostate and breast cancer TMAs demonstrated variable
ERb expression in differing cancer grades. In prostate tissue, pre-
vious reports have described an inverse correlation between ERb
expression and increasing Gleason grade of prostate cancer (Asgari
and Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014;
Horvath et al., 2001; Leav et al., 2001; Risbridger et al., 2007),
whereas others have reported an association between increased
ERb expression and higher Gleason grade (Zellweger et al., 2013) or
increased expression of ERb in bone and lymph node metastases
(Bouchal et al., 2011; Zhu et al., 2004). In our prostate TMA
(Fig. 5AeD) we observed high expression of ERb in the basal
epithelium of benign glands, with no expression in Gleason grade 3
cancer. Gleason grade 4 cancer showed weak nuclear staining of
ERb and in areas of Gleason grade 5 cancer, ERb nuclear expression
was of moderate intensity. In breast tissue, previous studies have
shown greatest ERb expression in benign tissue, with a gradual
Fig. 1. Validation of ERb antibodies using doxycycline-inducible MDA-MB-231-ERb cells. (A) MDA-MB-231-ERb cells were treated with doxycycline to induce ERb expression.
Untreated cells provided an ERb-negative control. Messenger RNA was extracted for qRT-PCR and protein for Western blotting. MDA-MB-231-ERbþ and MDA-MB-231-ERbe cells
were crosslinked and immunoprecipitated with antibody for RIME. (B) qRT-PCR conﬁrmed 100-fold induction of ERbmRNA in MDA-MB-231-ERbþ cells versus untreated MDA-MB-
231-ERbe cells. Data are mean ± S.D. of technical triplicate experiments. (C) Western blots of MDA-MB-231-ERbþ and MDA-MB-231-ERbe cells with the 8 antibodies undergoing
assessment. The MC10, CWK-F12, Abcam 288[14C8] and sc8974 antibodies detected bands of 59 kDa, with differential signal in the ERbþ versus ERbe conditions, indicating
speciﬁcity to ERb. GeneTex 70182 detected ERb, although there was non-speciﬁc signal at 65 kDa. Millipore 06-629 appears to detect ERb, although there is also a 59 kDa band in the
ERbe condition. Review of the RIME data suggests this may be cross-reactivity with LACTB. NCL-ER-BETA, the most commonly used ERb antibody, gives bands of the correct size for
ERb, but there is no difference between ERbe and ERbþ conditions, conﬁrming that this antibody is not speciﬁc to ERb.
A.W. Nelson et al. / Molecular and Cellular Endocrinology 440 (2017) 138e150 143decrease in expression associated with increasing cancer grade
(Guo et al., 2014; Omoto et al., 2002). Conversely, a non-statistically
signiﬁcant trend towards higher ERb expression in Grade 3 tumors
has also been reported (Myers et al., 2004). In our breast TMA
(Fig. 5FeI), we observed greatest expression of ERb in benign
epithelium, with a trend towards decreasing ERb expression asso-
ciated with increasing cancer grade.
One potential explanation for the inconsistencies in ERb tissue
expression is the presence of ERb splice-variant isoforms, which are
fully conserved in exons 1e6, but have differing C-terminal do-
mains (Leung et al., 2006). Different antibodies that bind either to
the conserved regions or only to the C-terminal domain of the full-
length ERb protein may therefore give differing results
(Supplementary Fig.1). This may particularly be the case in prostate
cancer, where it has been reported that ERb isoform expression
increases with the development of CRPC (Dey et al., 2012; Leung
et al., 2010). Whilst this is likely to have an impact, our datasuggest that some of the differing conclusions around ERb
expression in primary tissues are a direct result of certain in-
vestigations utilizing non-speciﬁc reagents that lack speciﬁcity for
ERb.
4. Discussion
Despite a large body of published literature, the role of ERb in
cancers of the prostate and breast is not clear. Contradictions be-
tween IHC ﬁndings and antibody-dependent molecular biology
methods have contributed to this uncertainty, particularly the lack
of clear consensus regarding correlation between tissue expression
of ERb and clinico-pathological parameters (Asgari andMorakabati,
2011; Attia and Ederveen, 2012; Bouchal et al., 2011; Dey et al.,
2014; Esslimani-Sahla et al., 2004; Guo et al., 2014; Hieken et al.,
2015; Horvath et al., 2001; Leav et al., 2001; Leygue and Murphy,
2013; Myers et al., 2004; Omoto et al., 2002; Risbridger et al., 2007;
Fig. 2. IHC validation of CWK-F12 ERb antibody in MDA-MB-231-ERb cell pellets. Nuclear staining is evident in MDA-MB-231-ERbþ cells and absent from the MDA-MB-231-
ERbe control, conﬁrming the speciﬁcity of CWK-F12 to ERb.
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et al., 2004).
Our results have demonstratedmarked variation in the ability of
commonly used commercially available ERb antibodies to accu-
rately detect ERb by Western blotting and protein puriﬁcation-MS
based methods. Most notably, NCL-ER-BETA, a commonly used
antibody (Ellem et al., 2014; Hussain et al., 2012; McPherson et al.,
2007; 2010; Morais-Santos et al., 2015; Oliveira et al., 2007;
Umekita et al., 2006; Yang et al., 2015; Zellweger et al., 2013) did
not detect ERb by any methodological approach. This antibody
consistently yields bands on Western blots of the appropriate size
for ERb (59 kDa) in all tested conditions (Figs. 1C and 3B), but we
have conﬁrmed that this protein band is not ERb through the use of
the MDA-MB-231-ERb inducible cell line system and the RIME
technique. As such, this non-speciﬁc ~59 kDa band is likely to be the
source of much of the controversy and confusion surrounding the
study and characterization of ERb. The PPG5/10 antibody targets
the C-terminus of wt ERb, and as such may be useful for dis-
tinguishing wt ERb from expression of ERb isoforms. PPG5/10
identiﬁed ERb in the MDA-MB-231-ERb cell line by RIME, and has
previously been shown to be ERb-speciﬁc by IHC in both an
inducible cell line model (Wu et al., 2012) and in breast tissue
(Carder et al., 2005). However, in our study this antibody did not
show speciﬁcity byWestern blot analysis (Fig. 1C). In their antibody
validation study, Carder et al. also assessed the Abcam 288[14C8]
antibody and found it to be ERb-speciﬁc for IHC in tissue (Carder
et al., 2005). Whilst our Western blotting data support this asser-
tion (Fig. 1C), our RIME data suggest that this antibody also puriﬁes
additional, non-speciﬁc peptides, and as such should be used with
caution for IP-based methods (Fig. 3B). Taken together, these
ﬁndings reassert the importance of validating antibodies for indi-
vidual experimental approaches, rather than assuming general
applicability across methodological platforms (Baker, 2015;
Bordeaux et al., 2010).
RIME was initially developed as a discovery tool to study the
interacting proteomes of transcription factors in an unbiased
manner (Mohammed et al., 2013). The advantage of using RIME in
antibody validation arises from being able to identify speciﬁc,
named peptides puriﬁed by an antibody, rather than relying on the
presence of a protein band of approximate size on a Western blot.
This is typiﬁed by the NCL-ER-BETA antibody, which gave bands on
Western blot in both ERbe and ERbþ conditions and no ERb pep-
tides identiﬁed by RIME. Taken together, these data conﬁrm that
this antibody is not speciﬁc to ERb. The non-commercially available
ERb antibodies tested (MC10 and CWK-F12) have been previouslyvalidated by other approaches (Choi et al., 2001; Wu et al., 2012)
and our results add further conﬁdence in their speciﬁcity using
multiple independent assays. By comparing the peptide coverage of
each antibody along with the ERb ranking (as a surrogate of spec-
iﬁcity) RIME facilitated an informed decision-making process in
selecting which antibody to carry forward to the cell-line charac-
terization. Our multi-modal approach to cell-line characterization
using both antibody-dependent (Western blotting and RIME) and
antibody-independent (qRT-PCR and PRM) approaches has shown
that low-passage, genotyped LNCaP and MCF-7 cell lines do not
express detectable ERb, despite numerous publications making
conclusions about ERb biology using these cell line models (Abd
Elmageed et al., 2013; Al-Bader et al., 2011; Bouchal et al., 2011;
Chen et al., 2009; Dey et al., 2014; Ellem et al., 2014; Fuqua et al.,
1999; Hinsche et al., 2015; Kim et al., 2002; Lau et al., 2000; Mak
et al., 2013; Weng et al., 2013; Yang et al., 2012, 2015). Whilst we
acknowledge that immortalized cell lines may have variable
expression of certain factors across passage numbers and labora-
tories (Masters, 2000), our data suggest the need for caution in
making this assumption with respect to ERb. Reassuringly, we have
conﬁrmed expression of ERb in prostate and breast tissue using the
validated CWK-F12 antibody. Our IHC study is not intended to be an
exhaustive analysis of ERb expression in prostate and breast tissue,
and we acknowledge the limitations presented by our small sample
size and lack of statistical correlation with clinico-pathological
parameters. We have however, demonstrated that the CWK-F12
ERb antibody is validated for IHC and in principle can be used for
larger scale assessment of ERb expression in tissue.
Epidemiological evidence suggests that estrogen and its re-
ceptors have important roles in the development and progression
of prostate cancer. Japanese men are known to have a very low
incidence of prostate cancer (Ross et al., 1992), and it has been
proposed that their traditional diet, which is high in ERb selective
phytoestrogens may exert a protective role (Andres et al., 2011;
Attia and Ederveen, 2012; Hori et al., 2011; Messina, 2010; Reiter
et al., 2011; Shen et al., 2000; Stettner et al., 2007; Thelen et al.,
2007, Thelen et al., 2005; Wuttke et al., 2002). Further evidence
from studies of ERb knockout mice (bERKO) shows a clear pheno-
type and tumor-suppressive effect of ERb (Ricke et al., 2008).
However, clinical trials of agents seemingly effective in vitro have
demonstrated no clinical beneﬁt of estrogen-selective agents in
prostate cancer (Bergan et al., 1999; Kim et al., 2002). There are
numerous explanations as to why this might be, for example,
expression of ERb in non-epithelial cell types (Gargett et al., 2002;
Pierdominici et al., 2010) modulating the tissue response to these
Fig. 3. RIME demonstrates speciﬁcity and peptide coverage of ERb antibodies. Eight ERb antibodies were assessed by RIME in MDA-MB-231-ERbþ/e cells. Coverage of the
protein relates to green areas on the peptide maps, indicating peptides identiﬁed by MS with false discovery rate of 1% (mean of 2 biological replicates). (A) E2F1 antibody was
applied to MDA-MB-231-ERbe and MDA-MB-231-ERbþ conditions as a positive control, as E2F1 is a ubiquitously expressed protein. (B) ERb antibody tests: ‘ERb ranking’ indicates
where ERb features in a list of proteins puriﬁed by the antibody, ranked by number of unique peptides identiﬁed in MS, giving an indication of antibody speciﬁcity. NCL-ER-BETA
failed to identify ERb. (C) Negative controls: All of the ERb antibodies were tested in MDA-MB-231-ERbe cells, to conﬁrm absence of ERb expression in the non-induced condition.
Mouse IgG antibodies were used to identify non-speciﬁc peptides pulled down by the IP. None of the IgG antibodies puriﬁed ERb.
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poorly validated reagents and inadequately characterized cancer
cell line models is an important contributing factor.
In the presented study, detailed validation of commonly used
ERb antibodies has demonstrated that some of these reagents
either detect ERb in speciﬁc experimental conditions only or lack
any speciﬁcity for ERb across multiple assays. ERb has been inves-
tigated in numerous cancers including prostate, breast, kidney (Yu
et al., 2013), colon (Dey et al., 2013), endometrium (Han et al., 2015),
ovary (Ciucci et al., 2014; Suzuki et al., 2008) bladder (Hsu et al.,
2013) and non-small cell lung cancer (He et al., 2015; Luo et al.,
2015) but in many cases, the ﬁndings are predicated on non-
speciﬁc reagents. As such, a re-evaluation of ERb expression and
biology is needed using reliable, speciﬁc reagents. Our determina-
tion of ERb antibody speciﬁcity will contribute towards clarifying
existing, conﬂicting data on the role of ERb in these diverse cancersand provide the necessary, validated tools with which to move
forward our understanding of ERb biology.
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